Skip to content
Screener

Cytokinetics CYTK EPS (Basic)

EPS (Basic) at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$1.62+153%
Eli Lilly logo
Eli LillyLLY
$7.95+26.2%
Merck & Co. logo
Merck & Co.MRK
-$0.54-131%
Lexicon Pharmaceuticals logo
Lexicon PharmaceuticalsLXRX
-$0.07-800%
Edgewise Therapeutics, Inc. logo
Edgewise Therapeutics, Inc.EWTX
-$0.46-7.0%
Capricor Therapeutics logo
Capricor TherapeuticsCAPR
-$0.59-11.3%

Other financials

Income statement

See full
Revenue$28.6M-57.1%
Operating income-$179.2M-60.7%
Net income-$198.8M-47.9%
EPS (diluted)-$1.50-33.9%

Balance sheet

See full
Cash & equivalents$255.3M+241%
Total debt$399.0M+31.2%
Total equity-$173.5M+52.9%
Total assets$1.9B+57.0%

Cash flow

See full
Operating cash flow-$159.8M-24.6%
CapEx$4.3M+4.6%
Free cash flow-$164.2M-24.0%

Valuation

See full
Market cap$11.05B+163%
Enterprise value$11.19B+153%
P/S163.3×+114×

Profitability

See full
Operating margin-1,046.1%+1,858pp
Net margin-1,321.1%+8,702pp
FCF margin-858.2%+1,799pp

Returns & leverage

See full
Return on equity-337.6%
Debt / equity2.2×
Current ratio6.7×-0.1×

Where this comes from

Reported directly by Cytokinetics in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.

The source filing: Cytokinetics’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:30 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-338217
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Change in fair value of derivative liabilities(1,100)3,0004002,600
Change in fair value of liabilities related to RPI Transactions2,400(14,600)800(10,700)
Net loss$(198,762)$(134,370)$(404,793)$(295,746)
Net loss per share — basic and diluted$(1.50)$(1.12)$(3.17)$(2.49)
Weighted-average number of shares used in computing net loss per share — basic and diluted132,086119,457127,704118,979
Other comprehensive (loss) gain:
Unrealized loss on available-for-sale securities, net(1,770)(851)(3,608)(1,392)
Foreign currency translation adjustments(444)(852)(848)(1,164)

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Cytokinetics's EPS (basic)?
Cytokinetics (CYTK) reported EPS (basic) of -$1.50 in Q2 2026.
How has Cytokinetics's EPS (basic) changed year-over-year?
Cytokinetics's EPS (basic) decreased by 33.9% year-over-year, from -$1.12 to -$1.50.
What is the long-term trend for Cytokinetics's EPS (basic)?
Over 4 years (2021 to 2025), Cytokinetics's EPS (basic) has grown at a 23.6% compound annual growth rate (CAGR), from -$2.80 to -$6.53.
What does EPS (basic) mean?
Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.

Ask your AI about Cytokinetics's eps (basic).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude